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Cystatin C (Cys-C) has been recently paid great attention as a better endogenous marker of the glomerular filtration 
rate than creatinine (Cr).   In this study, the usefulness of Cys-C was compared with Cr in terms of the estimation of 
the steady-state serum trough concentrations of digoxin in Japanese patients.   Forty patients treated with digoxin 
and 56 healthy elderly subjects were participated in this study.   The serum levels of Cys-C and Cr in the patients 
were higher than those in the healthy elderly subjects, but the increase of Cys-C was more predominant in the patients.   
Their levels were well-correlated for both of the healthy elderly subjects (r=0.691) and patients (r=0.774), but the serum 
concentrations of digoxin were better correlated with those of the reciprocal values of Cr (r=0.667) than those of Cys-C 
(r=0.383), presumably due to the fact that digoxin and Cr were excreted via both glomerular filtration and tubular 
secretion.   Cys-C is useful for the substratification of the patients diagnosed to have normal renal function with Cr of 
< 1.3 mg/dL into those with normal and pseudo-normal renal function, resulting in the corresponding serum 
concentrations of digoxin. 
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1.  Introduction 
Cystatin C (Cys-C) is a non-glycosylated cationic 
protein of 13.3 kDa, belonging to the cystatin superfamily 
of cysteine protease inhibitors [1, 2].   Cys-C is produced 
by all nucleated cells and is secreted into the blood at a 
constant rate [1, 2].   Cys-C is freely filtered through the 
normal glomerular membrane and completely 
reabsorbed, followed by catabolization by the proximal 
tubular cells [1, 2].   The biological fates of Cys-C are 
favorable as an endogenous marker of the glomerular 
filtration rate (GFR), similar to creatinine (Cr).   The 
n o r m a l  r a n g e  o f  C y s - C  i n  t h e  s e r u m  i s  f r o m  0 . 5 5  
(mean-1.96SD) to 0.99 (mean+1.96SD) mg/L in 
Japanese[3], with no inter-ethnic difference [4], and a 
higher level has been thought to be an index of renal 
dysfunction.   The superiority of Cys-C over Cr has 
been debated for the past decade, but in 2002, a 
meta-analysis of 46 reports concluded that Cys-C is a 
more useful marker for GFR than Cr [5].   A 
multinational expert meeting was held in Germany to 
summarize the latest findings also in 2002, and it was 
finally concluded that Cys-C is at least equal if not 
superior to Cr as a marker of GFR, and its independence 
from height, gender, age and muscle mass was 
highlighted to be advantageous for Cys-C when 
compared with Cr [1]. 
A recently published analysis with an extremely 
large number of subjects detected the effects of height, 
gender, age, weight, current cigarette smoking and 
C-reactive protein on the serum level of Cys-C [6], but it 
is still thought to be less susceptible to these effects than 
Cr.   For example, the serum level of Cys-C gives almost 
constant values for the subjects aged of more than 4 
months, whereas that of Cr depends more on age [2].   
In addition, recently, it has been demonstrated that 
Cys-C is more sensitive for moderate renal dysfunction 
than Cr [7-9], that is, the patients with a 24 h-Cr clearance 
of 51-70 mL/min show a significant increase in the serum 
level of Cys-C, but no alteration of Cr was found for such 
patients [7].   The lower sensitivity of Cr for moderate 
renal dysfunction might be due to its tubular secretion 
[10-12].   Moreover, the possibility of using the serum 
level of Cys-C to diagnose a certain class of heart diseases, 
including heart failure, has recently been suggested 
based on the fact that the serum level of Cys-C, not of Cr, 
w a s  h i g h e r  i n  s u c h  p a t i e n t s  [ 1 3 - 1 5 ] .    H o w e v e r ,  t h e  
PRIME study indicated that Cys-C is not a more 
predictive risk marker of coronary heart disease than 
CRP or interleukin-6, but could be useful in detecting 
moderate chronic renal disease [13]. 
In the present study, the usefulness of Cys-C was 
compared with Cr in terms of the estimation of 
p h a r m a c o k i n e t i c s  o f  d r u g s .    H e r e ,  t h e  a n a l y s i s  w a s  Int. J. Med. Sci. 2006, 3 
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performed for the patients treated with a cardiac 
glycoside, digoxin, since digoxin is mainly eliminated via 
the kidneys and its individual dose is adequately 
a d j u s t e d  b a s e d  o n  r e n a l  f u n c t i o n  [ 1 6 - 1 9 ] .    D u e  t o  
congestive heart failure and/or supraventricular 
tachyarrhythmias, the serum level of Cys-C, not of Cr, 
was expected to be higher, and their association with the 
serum concentration of digoxin in the steady-state was 
examined. 
2.  Materials and Methods 
Serum samples 
This study was conducted in conformity with 
Ethical Guidelines for Clinical Studies by the Ministry of 
Health, Labour and Welfare.   Serum samples were 
collected from 40 patients (25 males and 15 females) 
visiting Kobe University Hospital from January to July in 
2002.   These patients were maintained in a stable 
condition by the once daily oral dosing of digoxin at 0.17 
± 0.06 (0.06-0.25) mg/day, and the serum samples were 
subjected to the analysis of the serum concentration of 
digoxin, as well as the serum levels of Cys-C and Cr.   
Eight of 40 patients had coadministered with 
spironolactone (N=4), quinidine (N=2) and/or verapamil 
(N=3), which may influence the serum concentration of 
digoxin [20, 21]   Fifty-six unrelated healthy Japanese 
elderly subjects (37 males and 19 females) were also 
enrolled to determine the serum levels of Cys-C and Cr.   
Demographic data for these subjects is represented in 
Table 1. 
Table 1.    Demographic data for patients in this study 
Variable Healthy  elderly 
subjects 
Patients  P 
value 
Number (Male:Female)  56 (37:19)  40 (25:15)   
Age (years)  57.3 ± 2.0 
(55―62) 
72.0 ± 9.0 
(50―90) 
< 0.001 
Weight (kg)  61.6 ± 9.1 
(45.2―79.2) 
59.0 ± 11.4 
(38.0―85.0) 
0.234 
Height (cm)  162.3 ± 7.8 
(146.5―176.0) 
157.3 ± 8.6 
(139.4―173.0) 
< 0.01 
Serum cystatin C (mg/L)  0.86 ± 0.13 
(0.62―1.21) 
1.42 ± 0.58 
(0.76―3.07) 
< 0.001 
Serum creatinine 
(mg/dL) 
0.78 ± 0.17 
(0.48―1.18) 
1.08 ± 0.41 
(0.48―2.06) 
< 0.001 
* The values are the mean ± SD with the range in parentheses. 
Determination of serum levels of Cys-C, Cr and digoxin 
Serum levels of Cys-C and Cr were determined by 
Latex Nephrometry with a Behring Nepherometer II 
(Dade Behring LIMITED, Liederbach, Germany) and 
Creatininase F-DAOS assay with a Dimension RxL (Dade 
Behring LIMITED), respectively.   The serum 
concentrations of digoxin were by Particle Enhanced 
Turbidimetric Inhibition ImmunoAssay (PETINIA) with 
a Dimension Xpand-HM (Dade Behring LIMITED).     
The results were routinely validated to confirm 
acceptable precision and accuracy. 
Statistical analysis 
Values are given as the mean ± standard deviation 
(SD).   Statistical analysis was performed using SPSS ver. 
8.0.   The difference of the mean values between healthy 
elderly subjects and patients was calculated using 
Welch’s non-paired t-test for age, height, weight and 
serum levels of Cys-C and Cr.   Correlations between 
continuous variables were calculated using Pearson’s 
correlation coefficients in the patients.   Multiple 
comparisons were performed by analysis of variance 
(ANOVA) followed by Sheffé’s test for multiple 
comparisons provided that the variances of the groups 
were similar.   P values less than 0.05 (two-tailed) were 
considered to be significant. 
3.  Results 
As shown in Table 1 and Fig. 1, serum levels of 
Cys-C and Cr were 1.7- and 1.5-fold higher in the 
patients than those in the healthy elderly subjects, 
respectively, and the increase was more predominant for 
Cys-C than Cr.   Figure 2 showed the relationships 
between the serum levels of Cys-C and Cr in the healthy 
elderly subjects and patients.   The serum levels of 
Cys-C were well-correlated with those of Cr both in the 
healthy elderly subjects (Fig. 2a, r = 0.691) and patients 
(Fig. 2b, r = 0.774).   In the patients with normal renal 
function (serum level of Cr of < 1.3 mg/dL), a weak 
correlation was found with r = 0.298 (open square in Fig. 
2b). 
Figure 1. Histogram of serum levels of Cys-C and Cr. Fifty-six 
healthy elderly subjects (open column) and 40 patients treated 
with digoxin (closed column) were included in this analysis. 
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Figure 2. Relationships between serum levels of Cys-C and Cr 
in 56 healthy elderly subjects (a) and 40 patients (b). The open 
circles represent the healthy elderly subjects. The closed and 
open squares represent the patients with renal function being 
abnormal (serum level Cr, ≥1.3 mg/dL) and normal (serum 
level of Cr, <1.3 mg/dL). The regression lines were indicated 
for the healthy elderly subjects (solid in a, r=0.691), the 
patients with abnormal renal function (dotted in b, r =0.665) 
and the patients with normal function (solid in b, r=0.298). The 
correlation coefficient for the total patients was 0.774. 
 
 
Figure 3 shows the relationship between the serum 
trough concentrations of digoxin and the reciprocal 
values of the serum levels of Cys-C (Fig. 3a) and Cr (Fig. 
3b).   The correlation was better for Cr (r = 0.667) than 
Cys-C (r = 0.383).   Here, the serum level of Cys-C was 
used for substratification of the patients diagnosed as 
having normal renal function; i.e., Group I (normal), 
serum Cr of < 1.3 mg/dL and Cys-C of < 1.0 mg/L; 
Group II (pseudo-normal), serum Cr of < 1.3 mg/dL, but 
Cys-C of ≥ 1.0 mg/L; Group III (abnormal), serum Cr of ≥ 
1.3 mg/dL.   All patients belonging to Group III showed 
serum levels of Cys-C of 1.0 mg/L or more.   The serum 
concentrations of digoxin were 1.00 ± 0.32, 1.29 ± 0.36 and 
1.46 ± 0.41 ng/mL, respectively, with a significant 
difference between Groups I and III (Fig. 4, P < 0.05).   
There was no significant difference among the oral 
dosing amounts of digoxin in Groups I, II and III (0.18 ± 
0.07, 0.17 ± 0.08 and 0.19 ± 0.07 mg/day, respectively), 
and the dose-normalized serum concentration gave the 
difference between Groups I and III.   No significant 
differences in gender and age were also observed among 
Groups I, II and III (data not shown). 
Figure 3. Relationships between the serum trough 
concentrations of digoxin and the reciprocal values of serum 
levels of Cys-C (a) and Cr (b) in 18 patients treated with 
digoxin. The correlation coefficients were r=0.383 and 0.667 
for Cys-C and Cr, respectively.   
 Int. J. Med. Sci. 2006, 3 
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Figure 4. Serum concentration of digoxin for three patient 
groups substratified based on the serum levels of Cys-C and Cr. 
Group I (normal), serum Cr of <1.3mg/dL and Cys-C of 
<1.0mg/L; Group II (pseudo-normal), serum Cr of <1.3mg/dL, 
but Cys-C of ≥1.0mg/L; Group III (abnormal), serum Cr of 
≥1.3mg/dL. All patients belonging to Group III showed serum 
levels of Cys-C of 1.0mg/mL or more. Each bar represents the 
mean ± SD. *P<0.05, significantly different from Group I.     
 
4.  Discussion 
Digoxin shows a narrow therapeutic range, 
necessitating the routine monitoring of its serum 
concentration to maximize the therapeutic effects and 
minimize toxicities [16-19].   Since digoxin is mainly 
eliminated via the kidneys, the renal function of the 
patients and its alteration during therapy are important 
factors to conduct the monitoring and to understand the 
data on the serum concentration of digoxin [16-19].     
The serum level of Cr has been used to estimate the renal 
function, and usually the Cockcroft-Gault formula or the 
Modification of Diet in Renal Disease are usually applied 
[11, 22-24], however, the effects of gender, age, circadian 
rhythm and muscle mass on the serum level of Cr, and 
the lower sensitivity of Cr for moderate renal 
dysfunction are often raised as being problematic.   Due 
to the advantages in these areas, Cys-C is expected to be 
m o r e  u s e f u l  w h e n  c o m p a r e d  w i t h  C r  i n  t e r m s  o f  t h e  
estimation of digoxin pharmacokinetics. 
To date, two reports are published concerning the 
utility of the serum level of Cys-C to predict the renal 
clearance of digoxin [25, 26].   O ’ R i o r d a n  e t  a l .  h a v e  
reported that the serum level of Cys-C is no better than 
C r  a t  p r e d i c t i n g  d i g o x i n  c l earance in healthy elderly 
volunteers, whereas Hallberg and co-workers reported 
that, in the patients, the serum level of Cys-C correlated 
better to the serum concentration of digoxin [25, 26].   In 
the present study, it was found that the patients showed 
higher serum levels of Cys-C and Cr, when compared 
with the healthy elderly subjects (Table 1, Fig. 1).   The 
increase in the serum level was more predominant for 
Cys-C (Table 1, Fig. 2), being consistent with the reports 
showing that the serum levels were higher depending on 
heart diseases [13-15].   Nevertheless, the serum levels 
of Cys-C were well-correlated with those of Cr in the 
healthy elderly subjects (Fig. 2a, r = 0.691) and patients 
(Fig. 2b, r = 0.774).   After the stratification of the 
patients into normal and abnormal renal function with a 
Cr cut-off value of 1.3 mg/dL, it was indicated that the 
correlation was weaker, with r=0.298 for the patients 
with normal renal function, presumably due to the 
higher sensitivity of Cys-C for moderate renal 
dysfunction [7-9].   However, as shown in Fig. 3, the 
serum trough concentration of digoxin was better 
correlated with the reciprocal values of the serum levels 
of Cr (r = 0.667) than Cys-C (r = 0.383).   Cr was excreted 
into the urine via glomerular filtration and tubular 
secretion [10-12], similarly to digoxin [16-19].   Thus, the 
serum level of Cr might be useful for the prediction of 
the serum concentration of drugs excreted via glomerular 
filtration and tubular secretion, whereas the serum level 
of Cys-C might be useful for drugs excreted almost 
exclusively via glomerular filtration.   Cys-C might be 
useful for substratification of the patients diagnosed to 
have normal renal function with a Cr of < 1.3 mg/dL into 
the patients with “true” normal renal function and those 
with “pseudo” normal renal function, since Cys-C is 
more sensitive for the detection of moderate renal 
dysfunction [7-9].   As shown in Fig. 4, the serum 
concentrations of digoxin depended on the patient 
substratification.   It has been demonstrated that the 
serum concentration of digoxin at steady state was 
influenced by age, gender, weight, coadministered drugs, 
and dosage form, as well as renal function [20, 21].   Of 
these factors, oral dosing amounts of digoxin, age and 
gender were unlikely to be associated with the serum 
digoxin concentrations among Groups I, II and III.     
Meanwhile, four of 18 patients had coadministered with 
spironolactone (N=2), quinidine (N=1) or verapamil 
(N=1), which may influence the serum concentration of 
digoxin [25,26].   This study was conducted in a 
moderate population, and future large scale studies are 
needed to investigate the effect of coadministered 
medications. 
In summary, the usefulness of Cys-C was compared 
with Cr in terms of the estimation of the steady-state 
serum trough concentrations of digoxin in Japanese 
patients.   The serum levels of Cys-C and Cr in the 
patients were higher than those in the healthy elderly 
subjects, but the increase of Cys-C was more 
predominant in the patients, due to heart diseases.     
Their levels were well-correlated for both the healthy 
elderly subjects and patients, but the serum 
concentrations of digoxin were better correlated with 
those of the reciprocal values of Cr than those of Cys-C, 
presumably due to the fact that digoxin and Cr were 
excreted via both glomerular filtration and tubular 
secretion.   Cys-C is useful for the substratification of 
the patients diagnosed to have normal renal function 
with Cr of less than 1.3 mg/dL into those with normal 
and pseudo-normal renal function, resulting in the 
corresponding serum concentrations of digoxin. 
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